RE:RE:RE:Are the counters correct? If so, WOW Thanks for your response...the body's immune response certainly adds another level of treatment & protection to readily accessible tumors. To clarify, I was simply suggesting that the body's immune response to PDT may be dampened or wane more rapidly for certain "treated" tumors that are larger, more complex in structure, or simply less responsive/accessible to an effective treatment (I.e. close proximity of the tumor to vital structures/blood vessels, etc.). All or any of the above could make surgery prohibitive, or potentially increase surgical risk &/or make effective PDT (& an associated effective immune response) much more difficult to achieve.
On the other hand (& considering the full spectrum of treatment), the ability to develop a targeted/personalized cancer vaccine that uses specific tumor markers or antigens, including damps, would certainly recruit/boost the immune system to enhance overall treatment efficacy...as is being considered for the proposed treatment of GBM. Perhaps you were inferring this in your leading comment...
If approved, I see great potential of our PDT/ACT being used as both an adjuvant treatment & in combination with all forms of SOC (chemo, radiation, immunotherapy, etc.) across multiple indications. This type of use could very likely be our primary ticket to wealth, regardless of our ACT's solo or SOC potential. All imo & good luck...
Eoganacht wrote:
Plus there is the prospect of an immune response after treatment and this response is not necessarily restricted to treatment of superficial/accessible tumors. If Theralase's pdt ends up not being a stand-alone treatment for every type of cancer there is also the possibility of use as an adjuvant treatment such as in the intra-operative pdt for NSCLC that Roswell Park considered before deciding on the use of photofrin as a photosensitizer after surgery. The always cautious Dr. McFarland seems quite confident about an immune response:
"...Furthermore, we have very good evidence that our compounds elicit an immune response, leading to the suppression of metastases."
CancerSlayer wrote:
cashascars wrote: I've never seen anywhere on Stockhouse the amount of reads showing on TLT Bullboard. If the counter is displaying correctly, the amount of interest in this company is beyond any other that came before it. 700 or more reads is not uncommon today.
When the interest turns into investors we will see huge gains, bringing this company to a Market Cap it deserves. With a 2 treatment process to cure Bladder cancer and no serious discomfort or side affects, with many more potential cancer targets to come. My thoughts of a proper Market Cap is Much Much higher than present, all we need is more positive results from our phase 2 and in my optomistic view they are on thier way shortly so don't miss out on the move up into the dollars, now is the time to strike or pay more later.
Again I'm a little over the top some times with my opinions but correct me if I'm way out please.
cashascars
cashascars...for a car salesman, you're actually on point ; ). By offering a better ACT option for a finite number of cancers (the superficial/accessible tumors), the MC would certainly be in the tens of billions. An even bigger goldmine imo needs to be unleashed in the form effective/efficient treatment of interstitial or deep-seated cancers (I.e. via x-ray activation). This is where a Pharma partnership could expedite our path to unlimited wealth. You can forget about what I said in my last post re: a partnership with McFarland's private company...I'm getting old/less healthy & my money timeline is quickly shortening!